{"groups":[{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG000","title":"Cohort 1: Squamous Cell Carcinoma of the Skin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG001","title":"Cohort 2: Small Cell Malignancies of Nonpulmonary Origin"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG002","title":"Cohort 3: Adrenocortical Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG003","title":"Cohort 4: Medullary Renal Cell Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG004","title":"Cohort 5: Carcinoma of Unknown Primary"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG005","title":"Cohort 6: Penile Carcinoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG006","title":"Cohort 7: Vascular Sarcoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG007","title":"Cohort 8: Germ Cell Tumor"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG008","title":"Cohort 9: Paraganglioma-pheochromocytoma"},{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"FG009","title":"Cohort 10: Other Rare Tumor Histologies"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"21"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"11"},{"groupId":"FG008","numSubjects":"10"},{"groupId":"FG009","numSubjects":"20"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"}],"type":"Participant Choice"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"Progression and Exclusion from study due to changed diagnosis"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"}],"type":"Progression and withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"No evidence of tumor following radical surgery"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"29"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"13"},{"groupId":"FG009","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"22"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"26"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This is a single-center, open-label, phase II trial of pembrolizumab (MK-3475) in patients with and without programmed death-ligand 1 (PD-L1) positive advanced tumors conducted at the University of Texas MD Anderson Cancer Center"}